Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Research Reports Initiation on Medical Laboratories & Research Stocks -- Quest Diagnostics, Bruker, Organovo, and Alere

Chelmsford Park SA
Posted on: 31 Aug 16

NEW YORK, August 31, 2016 /PRNewswire/ -- draws investors' attention to these Medical Laboratories and Research equities: Quest Diagnostics Inc. (NYSE: DGX), Bruker Corp. (NASDAQ: BRKR), Organovo Holdings Inc. (NASDAQ: ONVO), and Alere Inc. (NYSE: ALR). Industry growth is influenced by a number of trends, which include demographics, emerging economies, biotech advances in genetics, and pathogen evolution. Learn more about these stocks by downloading their free report at:

Quest Diagnostics  

On Tuesday, shares in Madison, New Jersey headquartered Quest Diagnostics Inc. recorded a trading volume of 896,963 shares. The stock ended the session 0.94% lower at $83.54. The Company's shares have gained 8.63% in the previous three months and 19.33% on an YTD basis. The stock is trading 0.39% above its 50-day moving average and 14.00% above its 200-day moving average. Moreover, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have a Relative Strength Index (RSI) of 45.08.

On August 3rd, 2016 Quest Diagnostics announced that it has teamed up with AncestryDNA, to help meet the rapidly growing consumer demand for genetic tests that provide insights into genetic ethnicity, origins, and other factors. Under a new multi-year global collaboration, Quest Diagnostics will provide genotyping test services on behalf of Ancestry's AncestryDNA, a service that today identifies and quantifies an individual's ethnic origins based on results of DNA testing. In just over four years, AncestryDNA has grown to become the world's largest consumer genomics provider, with more than two million consumer DNA samples in its database. The free research report on DGX is available at:


Billerica, Massachusetts headquartered Bruker Corp.'s stock closed the day 1.33% lower at $22.32 with a total trading volume of 849,059 shares. Shares of the Company, which together with its subsidiaries, designs and manufactures scientific instruments, and analytical and diagnostic solutions worldwide, are trading 3.97% below their 50-day moving average. The stock has an RSI of 47.20.

On August 03rd, 2016, research firm Mizuho reiterated its 'Neutral' rating on the Company's stock with a decrease of the target price from $28 a share to $23 a share.

On August 22nd, 2016, Bruker announced the next-generation version 2.0 of its advanced MetaboScape® solution for metabolomics research and routine analysis. This integrated solution for non-targeted metabolomics links impact II LC-QTOF-MS/MS data to the underlying biology based on metabolic pathway mapping. MetaboScape 2.0 enables the annotation of unknown compounds and provides scientists with a higher degree of confidence in the identification of known metabolites through the use of high-resolution, accurate mass MS/MS fragment information. The complimentary report on BRKR can be downloaded at:

Organovo Holdings  

Shares in San Diego, California headquartered Organovo Holdings Inc. recorded a trading volume of 415,249 shares. The stock ended yesterday's trading session flat at $3.91. The Company's shares have advanced 33.45% in the previous three months and 57.03% since the start of this year. The stock is trading above its 200-day moving average by 35.07%. Furthermore, shares of Organovo Holdings, which focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs, have an RSI of 40.76.

On August 4th, 2016, Organovo reported that net loss was $8.8 million, or $0.09 per share, for Q1 FY17, as compared to $8.5 million, or $0.10 per share, for Q1 FY16. Organovo reported fiscal Q1 total revenue of $0.9 million, which consisted largely of product and service revenue. The company's total revenue increased 191% versus the comparable period of FY16. Visit us today and download our complete research report on ONVO for free at:


Waltham, Massachusetts headquartered Alere Inc.'s stock finished the session 0.10% lower at $39.31 with a total trading volume of 706,164 shares. The Company's shares have advanced 6.33% in the last one month and 0.56% since the start of this year. The stock is trading below its 50-day moving average by 2.46%. Additionally, shares of Alere, which provides professional diagnostic products and services for infectious and cardiometabolic disease, and toxicology in the US, Europe, and internationally, have an RSI of 47.24.

On August 26th, 2016, Alere announced that it has filed a complaint against Abbott in Delaware Chancery Court on August 25, 2016. The case seeks to compel Abbott to fulfill its obligations under the terms of the merger agreement to take all actions necessary to promptly obtain all required anti-trust approvals. Alere stated that it will take all actions necessary to protect the interests of Alere's shareholders, enforce Alere's rights under the merger agreement and compel Abbott to complete the transaction in accordance with its terms. Get free access to your technical report on ALR at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number:  +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

For more information:

Editor's Details

Mike Wood

Last updated on: 31/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.